Alexandra K. Gold

Alexandra K. Gold

Auto-generated profile, based on publicly available information

Alexandra K. Gold

Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2019 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
AGAlexandra K. Gold
Alexandra K. Gold
GKGustavo Kinrys
Gustavo Kinrys

18 August 2021 in Psychology, Health & Medicine
Verified
Journal Article
Closed access
MMMegan A. Milligan
Megan A. Milligan
DHDanielle L. Hoyt
Danielle L. Hoyt
AGAlexandra K. Gold
Alexandra K. Gold
MHMichele Hiserodt
Michele Hiserodt
MOMichael W. Otto
Michael W. Otto
Given recent declines in US vaccination rates and the emergence of COVID-19 vaccines, identifying sociodemographic influencers of vaccine willingness holds importance for developing effective public health campaigns aimed at enhancing nationwide COVID-19 vaccine acceptance. The present study utilized a hierarchical binary logistic regression model to assess demographic variables (age, gender, race/ethnicity, pre-existing medical conditions), political party membership, religious affiliation, level of religiosity, and fear of COVID-19 as predictors of COVID-19 vaccine acceptance (‘Yes’, would receive a vaccine or ‘No’, would not receive a vaccine) in a national sample of US adults (N = 249). Participants were recruited from Amazon’s Mechanical Turk (MTurk) and completed several online questionnaires pertaining to mental health, health behaviors, and responses to the COVID-19 pandemic. Both Democratic party membership and decreased level of religiosity predicted acceptance of a COVID-19 vaccine. This investigation supports political party membership and religiosity as influencers of COVID-19 vaccine willingness and suggests that these variables could represent potential targets for public health interventions aimed at increasing vaccine adoption.

30 September 2019 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
AGAlexandra K. Gold
Alexandra K. Gold
AOAna Claudia Ornelas
Ana Claudia Ornelas
PCPatricia Cirillo
Patricia Cirillo
MCMarco Antonio Caldieraro
Marco Antonio Caldieraro
ANAntonio E Nardi
Antonio E Nardi
GKGustavo Kinrys
Gustavo Kinrys
Background: Many patients with bipolar disorder (BD) fail to experience benefit following traditional pharmacotherapy, necessitating alternative treatment options that will enable such patients to achieve remission. Transcranial magnetic stimulation (TMS) is a relatively new, noninvasive neuromodulation technique that involves the application of magnetic pulses on hyperactive or hypoactive cortical brain areas. We evaluated the existing literature on TMS as a treatment for BD across varied mood states.Methods: We searched PubMed up to October 2018 for original data articles published in English that evaluated outcomes in a bipolar sample across depressive, manic, mixed, and maintenance phases of BD.Results: Clinical trials of TMS for BD particularly suggest the potential of repetitive TMS for reducing depressive symptoms. Studies of TMS for mania have yielded more mixed findings. Few studies have evaluated TMS in other phases of the bipolar illness. TMS is generally associated with mild side effects though, in a few studies, it has been shown to contribute to a manic switch in previously depressed bipolar patients.Conclusions: Transcranial magnetic stimulation is a promising approach for treating patients with BD who have failed to respond to pharmacological or psychosocial treatment. Future research should more clearly elucidate which TMS protocols may be most effective for a given bipolar patient.

29 March 2018 in The American Journal on Addictions
Verified
Journal Article
Closed access
PDF file
AGAlexandra K. Gold
Alexandra K. Gold
MOMichael W. Otto
Michael W. Otto
TDThilo Deckersbach
Thilo Deckersbach
LSLouisa G. Sylvia
Louisa G. Sylvia
ANAndrew A. Nierenberg
Andrew A. Nierenberg
GKGustavo Kinrys
Gustavo Kinrys

14 February 2019 in Cognitive Behaviour Therapy
Verified
Journal Article
Closed access
AGAlexandra K. Gold
Alexandra K. Gold
GSGeorgia Stathopoulou
Georgia Stathopoulou
MOMichael W. Otto
Michael W. Otto
Refining the mechanisms behind illicit drug use is an important factor for improving the quality of clinical care. Research in alcohol, marijuana, and nicotine use disorders have linked coping motives (e.g. using substances to ameliorate negative emotional states) to problematic substance use. We evaluated the link between emotion regulation difficulties (as assessed via the difficulties in emotion regulation scale [DERS]) and motives for drug use (as assessed via the Drug Use Motives Questionnaire) among individuals (n = 68) with opioid use disorders who were in methadone maintenance treatment. We found that the DERS total score was significantly associated with coping motives for use. Nonacceptance of emotional responses was the only DERS domain that offered nonredundant prediction of coping motives. These findings highlight the relevance of specific emotion regulation deficits in motives for illicit drug use among individuals with opioid use disorders and may help inform targeted cognitive-behavioral treatments in this population.

19 February 2021 in Cognitive Behaviour Therapy
Verified
Journal Article
Closed access
AGAlexandra K. Gold
Alexandra K. Gold
DHDanielle L. Hoyt
Danielle L. Hoyt
MMMegan Milligan
Megan Milligan
MHMichele L. Hiserodt
Michele L. Hiserodt
JSJake Samora
Jake Samora
MOMichael W. Otto
Michael W. Otto
Preliminary data suggest that cigarette smokers could have an increased mortality risk from the novel coronavirus (SARS-CoV-2), and that certain factors (e.g., increased age, medical comorbidities) can also increase risk of poor coronavirus disease (COVID-19) outcomes. Between April 30th, 2020 and May 28th, 2020, we evaluated self-reported changes in recent smoking patterns and motivation to quit smoking among current daily cigarette smokers (N = 103) on Amazon Mechanical Turk. We also assessed the relationship of these outcomes to age, medical comorbidity status, and fear of COVID-19. Most participants (68.9%) reported smoking less frequently than usual in the last 28 days. Among daily smokers, increased fear of COVID-19 predicted increased motivation to quit smoking and actual smoking reductions (ps < .05). Endorsement of one or more medical comorbidities, but not increased age, predicted increased motivation to quit smoking (p < .05). These data suggest the potentially greater relevance of psychological factors (e.g., fear of COVID-19) over external risk factors (e.g., medical comorbidity, increased age) on motivation to quit smoking and actual reductions in smoking patterns, and may reflect that the pandemic is a suitable time for offering smoking cessation intervention.